ImmunoGen Inc (IMGN)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | PHARMACEUTICALS |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Mark J. Enyedy |
| Employees: | 110 |
| Web site: | immunogen.com |
|
830 WINTER ST, WALTHAM, MA, 02451
(781)895-0600
| |
• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
ImmunoGen, Inc. develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer.
Please log in first to see chart